萊茵生物(002166.SZ):上半年淨利預降65%-75%
格隆匯7月14日丨萊茵生物(002166.SZ)公佈2023年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利3333.31萬元–4666.64萬元,比上年同期下降65%-75%;扣除非經常性損益後的淨利潤盈利337.10萬元–1451.41萬元,比上年同期下降87%-97%;基本每股收益盈利0.045元/股–0.063元/股。
2023年上半年,受宏觀經濟下行、短期行業去庫存加劇及公司競爭策略調整的影響,導致公司上半年營業收入及毛利率較上年同期均呈現不同程度的下滑。同時,工業大麻市場仍處於逐漸復甦狀態,公司陸續交付訂單,但業務體量暫無法覆蓋工廠運營費用與成本,導致上半年產生一定的停工損失費。綜上,導致公司上半年的淨利潤大幅收窄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.